EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Randomisierte kontrollierte Studie

Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA

Sonia Luque Pardos, William Hope, Antigone Kotsaki, Shampa Das iD, Evangelos J Giamarellos-Bourboulis iD, Theano Kontopoulouk, Karolina Akinosoglou, Miriam O'Hare, Marie L G Attwood iD, Karen E Bowker, Alan R Noel, Andrew M Lovering und 3 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae363 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Sonia Luque Pardos und 14 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Farmacia, Parc de Salut Mar, Barcelona, Spain. Hauptthemen laut MEDLINE: Rifampin, Minocycline, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: European 7th Framework Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The population pharmacokinetics/pharmacodynamics (PK/PD) of minocycline, rifampicin and linezolid in patients with complicated skin and soft tissue infections (cSSTIs) caused by MRSA are described.

Methods

Samples were collected in a Phase 4 study of oral minocycline plus rifampicin versus linezolid showing minocycline plus rifampicin to be non-inferior to linezolid. Antibiotics were assayed by HPLC or LC-MS, and a population PK model was developed using Pmetrics. The association between PK/PD indices and patient outcomes was explored.

Results

A three-compartment model (with an absorption compartment) with first-order input and elimination best described the data for the three drugs. No covariates were included in the final model. The population median values (95% credibility limits) of the clearance and volume of distribution were 7.412 L/h (5.121–8.361) and 14.155 L (6.799–33.901) for minocycline, 5.683 L/h (3.703–7.726) and 7.736 L (6.031–8.948) for rifampicin, and 1.970 L/h (1.326–2.499) and 20.169 L (12.857–32.629) for linezolid, respectively. Maximum a posteriori probability-Bayesian estimation plots of observed versus predicted had a slope of 0.999 r20.967 for minocycline, slope 0.998 r20.769 for rifampicin and slope 0.998 r20.895 for linezolid. PK/PD indices were not related to clinical outcome. Taking a translational minocycline fAUC24h/MIC target of >0.5 for minocycline in the presence of rifampicin, 96% (49/51) of patients reached the target.

Conclusions

Population PK models of minocycline, rifampicin and linezolid were developed in patients with MRSA cSSTI and almost all patients reached the predefined PD index targets. As a result, neither AUC, MIC nor the AUC/MIC ratio could be related to clinical outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMinocyclineAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusLinezolidHumansMaleMiddle AgedFemaleAgedAdultStaphylococcal Skin InfectionsMicrobial Sensitivity TestsAged, 80 and overYoung AdultTreatment OutcomeSoft Tissue InfectionsDrug Therapy, Combination

Substanzen

RifampinMinocyclineAnti-Bacterial AgentsLinezolid

Autor:innen und Institutionen

  • Servei de Farmacia, Parc de Salut Mar, Barcelona, Spain.
  • Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7BE, UK.
  • 4th Department of Internal Medicine, National and Kapodistrain University of Athens Medical School, Athens, Greece.
  • 1st Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece.
  • Department of Internal Medicine, University of Patrea Medical School, Rion, Greece.
  • Micron Research Ltd, 109B Lancaster Way, Ely CB6 3 NX, UK.

ORCID-Profile: Shampa Das, Evangelos J Giamarellos-Bourboulis, Marie L G Attwood, Rebecca N Evans

Förderung

  • European 7th Framework Program

Zitieren

APA

Pardos, S. L., Hope, W., Kotsaki, A., Das, S., Giamarellos-Bourboulis, E. J., Kontopoulouk, T., Akinosoglou, K., O'Hare, M., Attwood, M. L. G., Bowker, K. E., Noel, A. R., Lovering, A. M., Bayliss, M. A. J., Evans, R. N., & MacGowan, A. P. (2024). Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae363

Vancouver

Pardos SL, Hope W, Kotsaki A, Das S, Giamarellos-Bourboulis EJ, Kontopoulouk T, et al. Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae363

BibTeX
@article{Pardos2024,
  author = {Pardos, Sonia Luque and Hope, William and Kotsaki, Antigone and Das, Shampa and Giamarellos-Bourboulis, Evangelos J and Kontopoulouk, Theano and Akinosoglou, Karolina and O'Hare, Miriam and Attwood, Marie L G and Bowker, Karen E and Noel, Alan R and Lovering, Andrew M and Bayliss, Mark A J and Evans, Rebecca N and MacGowan, Alasdair P},
  title = {Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae363}
}
Kostenlos starten →